Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Atea Pharmaceuticals, Inc. (AVIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update"
06/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update"
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A EcoR1 Capital, LLC reports a 7.4% stake in Atea Pharmaceuticals, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.3% stake in Atea Pharmaceuticals Inc.
02/09/2023 SC 13G/A FMR LLC reports a 14.1% stake in ATEA PHARMACEUTICALS INC
01/24/2023 SC 13G/A BlackRock Inc. reports a 9.6% stake in Atea Pharmaceuticals, Inc.
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/13/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
Docs: "Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update"
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/28/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/28/2022 10-K Annual Report for the period ended December 31, 2021
02/28/2022 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/28/2022 8-K Quarterly results
02/16/2022 SC 13G/A Morningside Venture Investments Ltd reports a 0% stake in ATEA PHARMACEUTICALS, INC.
02/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2022 SC 13G/A Cormorant Asset Management, LP reports a 2% stake in Atea Pharmaceuticals, Inc.
02/10/2022 SC 13G/A Sommadossi Jean-Pierre reports a 8.4% stake in Atea Pharmaceuticals, Inc.
02/09/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy